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Somatostatin receptors are present in the normal adrenal cortex and medulla.
These receptors are also expressed by tumors that cause Cushing's syndrome
and by pheochromocytomas. Somatostatin analogues such as octreotide have
been developed to target somatostatin receptors for diagnostic and therapeutic
purposes. This article reviews the current knowledge ofthe biology of somato-
statin receptors in the normal adrenal gland and in adrenal tumors and defines
the current role of the somatostatin receptor in the diagnosis, staging and man-
agement ofCushing's syndrome and pheochromocytomas.
INTRODUCTION
The adrenal glands are paired endocrine glands located atop the kidneys. Each adren-
al gland has a cortex and a medulla. The adrenal cortex is subdivided into three layers,
each with a distinct role in hormone production. The outermost "zona glomerulosa" is the
site of aldosterone production, the middle "zona fasciculata" produces cortisol and the
innermost "zona reticularis" is the site of adrenal androgen production. The adrenal
medulla is part ofthe neuroendocrine system, receiving sympathetic innervation and pro-
ducing catecholamines, epinephrine andnorepinephrine. Researchers have begun to inves-
tigate the importance of the presence of somatostatin hormone receptors on adrenal tis-
sues. The purpose of this article is to review what is currently known about the presence
of somatostatin receptors in normal adrenal tissue and adrenal tumors. Next, the use of
radiolabeled somatostatin analogues for the diagnosis of adrenal pathology will be dis-
cussed. Finally, the potential use of somatostatin analogues for the treatment of adrenal
disorders will also be addressed.
NORMAL ADRENAL SOMATOSTATIN RECEPTORS
Somatostatin, also called somatotropin releasing inhibitory hormone (SRIH)b, is a
peptide hormone that is present in two predominant isoforms: a 14 amino acid structure
(SRIH-14) and a 28 amino acid form (SRIH-28) [1, 2, 3]. Each of these naturally occur-
ring isoforms binds to all five of the known somatostatin receptors (SSTR1I5) that have
been identified in humans [4]. When five normal human adrenals were examined by
a To whom all correspondence shouldbe addressed: John W. Kennedy, M.D., 18 Hedgecroft Drive,
Trenton, NJ 08638. Tel.: 609-818-1754; E-mail:jappelken@juno.com.
b Abbreviations: SRIH, somatotropin releasing inhibitory hormone (somatostatin); SSTR
somatostatin receptor subtype 1-5; 1251, iodine-125; mRNA, messenger ribonucleic acid; cDgA,
complementary deoxyribonucleic acid; ACTH, adrenocorticotropic hormone (corticotropin); CRH,
corticotropin releasing hormone; MRI, magnetic resonance imaging; IPS, inferior petrosal sinus;
SRS, somatostatin receptor scintigraphy; MBq, milli-barq; llIn-DPTA-Phe1-octreotide, indium
11l-diethylene triamine penta-acetic acidphenylalanine-l-octreotide; mCi, milli-Curie; 131I-MIBG,
Iodine 131-meta-iodobenzylguanidine; SPECT, single photon emission computed tomography; CT,
computed tomography.
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radioautography for specific binding of radiolabeled somatostatin (1251-SRIH), somato-
statin receptors were identified in both cortex and medulla, but specific binding was much
more intense in the normal human adrenal medulla [5]. In a study oftwo normal human
adrenal glands, messenger ribonucleic acid (mRNA) for each of the five SSTR subtypes
was expressed, with SSTR2 predominating [5]. In summary, the normal human adrenal
gland contains all five ofthe known somatostatin receptor subtypes. The predominant iso-
form is SSTR2, and the receptors are concentrated in the adrenal medulla.
Animal studies have been performed in an attempt to gain further insight into the role
of somatostatin receptors within the adrenal cortex. In salt-depleted rats, the site ofhigh-
est somatostatin receptor density in the adrenal cortex is the zona glomerulosa [6, 7].
Administration of somatostatin to these animals specifically inhibits angiotensin II-stim-
ulated aldosterone production. In addition, somatostatin inhibits the basal and angiotensin
II-stimulated growth of the rat zona glomerulosa [8]. These animal studies demonstrate
that under the given experimental conditions, rat adrenal cortical somatostatin receptors
are located mainly in the zona glomerulosa, regulating angiotensin Il-mediated aldos-
terone secretion and growth ofthe adrenal cortex.
SOMATOSTATIN RECEPTORS AND ADRENAL DISEASE
Pheochromocytomas
Pheochromocytomas are neuroendocrine tumors arising from the adrenal medulla,
which characteristically overs-secrete catecholamines, producing a clinical syndrome of
paroxysmal hypertension, heart palpitations and profuse sweating [9, 10]. Paragangliomas
are similar tumors, which arise from sympathetic ganglionic tissue and are also known as
ectopic or extra-adrenal pheochromocytomas. Approximately 10 percent ofpheochromo-
cytomas are malignant. In a study of51 adrenal pheochromocytomas (46 benign and five
malignant), 37 of51 had SRIH receptors (73 percent) detectable by 125I-SRIH radioauto-
graphy. Only 36 percent ofthe tumors studied were classified as containing a high densi-
ty of receptors [11]. However, 13 of 14 paragangliomas studied in the same paper were
SRIH receptor positive (93 percent), with 43 percent considered to be ofhigh density.
In a separate study of 33 human pheochromocytomas (22 benign adrenal, six extra-
adrenal and five malignant), SSTR was detected in all tumors, but 12/33 pheochromocy-
tomas had a receptor density that was at or below the normal range [5]. In these same
tumors, specific binding ofradiolabeled somatostatin (1251-SRIH) was found to be evenly
distributed over the tumor tissue and was on average significantly increased (two-fold)
over normal adrenal medullary tissue. There was no detectable difference in the density of
SSTR expression among the subgroups of pheochromocytomas studied. A substudy of
SSTR mRNAs quantified by amplification of their respective cDNAs in eight pheochro-
mocytomas (four benign adrenal, two benign extra-adrenal and two malignant), reported
in the same paper, revealed that all five SSTR subtypes may be expressed by pheochro-
mocytomas, with multiple subtypes expressed by a single tumor. This confirmed a previ-
ous study by a separate group who identifiedmultipleSSTRI and SSTR2 isoforms in each
three of the three pheochromocytomas examined [12]. The predominant somatostatin
receptor subtypes expressed by pheochromocytomas are SSTR2 and SSTR4 [5]. Four out
of five malignant tumors had normal or low SSTR expression, and these tumors had a
poorer clinical outcome than the single malignant tumor with increased receptor density.
In summary, the majority of pheochromocytomas express somatostatin receptors at simi-
lar or increased density compared to normal adrenal medullary tissue. Receptor subtype
expression and density vary case-to-case.
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Adrenal cortical tumors
No systematic study of somatostatin receptors in adrenal cortical tumors has been
published to date. Despite this dearth of scientific information, clinicians have attempted
to target somatostatin receptors on those clinically challenging tumors which overproduce
cortisol and are located outside the adrenal gland. The results of these clinical efforts at
diagnosis and therapy are discussed below.
SOMATOSTATIN RECEPTOR SCINTIGRAPHY
Octreotide is a man-made eight amino acid analogue of the 14 amino acid naturally
occurring hormone somatostatin. Octreotide has an elimination half-life of two hours,
much longer than the three-minute circulation half-life of somatostatin, and is thus better
suited for use in the diagnosis of somatostatin receptor positive tumors [3, 13]. 11lln-pen-
tetreotide (OctreoScan®, Mallinckrodt Medical Inc., St. Louis, Missouri) is currently
available as a diagnostic agent in the United States. Its use in the management of tumors
affecting the adrenal gland is summarized below.
ACTH-dependent Cushing's syndrome
Octreotide scanning has proven helpful in the diagnosis of selected cases of extra-
adrenal tumors producing adrenocorticotropic hormone (corticotropin orACTH) or corti-
cotropin releasing hormone (CRH). Excess secretion ofthese hormones results in an over-
production of cortisol from the adrenal gland, a condition called ACTH-dependent
Cushing's syndrome. Patients present with hypertension, central obesity, diabetes, easy
bruising, rounded facies, plethora, hyperpigmentation and purple abdominal striae.
ACTH-dependent Cushing's Syndrome may stem from either a primary pituitary tumor
(Cushing's disease) or from an ectopic source. The most common ectopic tumor is a car-
cinoid tumor located in the chest or gut. Somatostatin receptor scintigraphy has proven
most beneficial for diagnosing occult ectopic tumors.
Patients are diagnosed with ACTH-dependent Cushing's Syndrome based upon ele-
vated serum or urine cortisol measurements, with simultaneous elevation ofACTH [14].
Furtherbiochemical suppression tests are then performed in an attempt to differentiate the
source of the abnormal hormone production either to the pituitary or periphery [14, 15].
When these studies are non-diagnostic, the pituitary may be visualized with magnetic res-
onance imaging (MRI) to attempt to identify obvious disease. In equivocal cases, inferior
petrosal sinus (IPS) sampling forACTH with and without CRH stimulation is performed
to document whether the excess hormone production is of a central pituitary or peripher-
al ectopic source [16]. It is in those cases isolated to the periphery that somatostatin recep-
tor scintigraphy has been of most diagnostic benefit.
Initial evidence for the potential benefit of SRS was tested in a study of 10 patients
with ectopic Cushing's syndrome (nine ectopic ACTH-secreting tumors and one CRH-
secreting tumor) with a total of 24 known localizations and one occult tumor. In five of
the 10 patients, SRS identified all known localizations, and in eight of 10, identified at
least one known site. Nineteen ofthe 24 known localizations were correctly identified (79
percent) [17, 18]. The one occult tumor remained occult despite the octreotide scan. No
information about possible false-positive localizations was included in the report. Thus,
this report suggested that in up to 79 percent oflesions may be identified by SRS in cases
ofectopic Cushing's, localizing all sites in 50 percent ofsubjects. In this same study, nine
other patients with pituitary or adrenal sources for their excess hormone production (five
pituitary Cushing's disease, three Nelson's syndrome and one adrenal adenoma) had neg-
ative scans, suggesting these tumors do not overexpress somatostatin receptors.
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Actual tumor size is of little importance in octreotide scanning. It is the increased
density ofsomatostatin receptors expressed by the tumors compared with neighboring tis-
sues that allows the tumor to be visualized [19]. For this reason, tiny producing tumors
that overexpress somatostatin receptors may be easily visualized withoctreotide scanning.
Three additional case reports have been published in which SRS localized minute carci-
noid tumors (1.0 cm, 0.9 cm and 0.6 cm) that were responsible for ACTH-dependent
Cushing's syndrome in patients. [20, 21, 22]. SRS identification (two patients) and con-
firmation (one patient) ofthese small lesions was clinically important as their signal char-
acteristics were difficult to distinguish from pulmonary blood vessels by conventional
imaging, and surgical removal ofthese lesions leads to prompt cure.
SRS andpheochromocytoma
Despite the extensive in vitro data that has been published regarding the presence of
somatostatin receptors on pheochromocytomas, the published clinical experience with
somatostatin analogues such as radiolabeled octreotide to image pheochromoctomas in
vivo has been limited to two small European case series. In the largest series published to
date, 12 out of 14 pathologically confirmed pheochromocytomas (86 percent) were iden-
tified by lllln-DPTA-Phel-Octreotide (222 MBq intravenous with planar imaging four
hours post-injection and planar plus SPECT imaging at 24 hours) [23]. This same group
reported a diagnostic sensitivity of 93 percent for the localization ofparagangliomas (26
out of28) using the same protocol [23, 24]. No information regarding false positive local-
izations was stated.
Our own preliminary experience with SRS and pheochromocytomas involves an
ongoing comparison of SRS with standard imaging modalities (CT or MRI) at the
Brigham and Women's Hospital in Boston [25]. Patients with a high clinical suspicion of
pheochromocytoma based uponbiochemical testing and thepresence ofa CT orMRI doc-
umented lesion underwent SRS (6.0 mCi I1IIn-pentetreotide with planar imaging at four
and 24 hours and SPECT imaging at 24 hours). All suspicious lesions were then evaluat-
ed at surgery and identified withpathology. SRS accurately localized five ofsix pheochro-
mocytomas. Two benign lesions felt to be suspicious for pheochromocytoma based on
MRI were appropriately negative on SRS. Thus, this small series demonstrates that SRS
has a sensitivity of 83 percent for pheochromocytoma (five of six lesions), comparable to
the European experience. In our experience, SRS localizes adrenal, ectopic and metastat-
ic pheochromocytomas. Prospective multi-center studies are needed in order to obtain the
necessary numbers of patients to more firmly establish the sensitivity and specificity of
this test.
The other published study addresses the important clinical consideration of the rela-
tive sensitivity ofSRS compared to the current gold standard nuclear medicine compound
utilized in the evaluation of pheochromocytoma, MIBG [26]. The sensitivity of MIBG
scanning forpheochromocytoma has been well established, based in part on aprospective
study of 109 patients with a high clinical suspicion for pheochromocytoma who received
extensive biochemical testing, CT scanning and a diagnostic 131I-MIBG (45 surgically
confirmed cases of pheochromocytoma, 20 non-pheochromocytoma adrenal masses and
44 considered clinically free ofdisease based on the diagnostic workup) [9]. MIBG had a
sensitivity of 78 percent (35 out of45 confirmed pheochromocytomas imaged), a speci-
ficity of 100 percent (0 out of 20 adrenal adenomas imaged), yielding a negative predic-
tive value of 87 percent and a positive predictive value of 100 percent in this series.
SRS using llIn-DPTA-Phel-Octreotide (130-187 MBq intravenous with planar
imaging at four, 24 and 48 hours and SPECT imaging at 24 hours) was compared with
MIBG scanning in 10 patients with metastatic pheochromocytomas and three patients
with paragangliomas [26]. The type and dose of MIBG varied widely among the study
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subjects. Among the 10 pheochromocytoma subjects, six received a diagnostic dose of
MIBG (five received 74 MBq 1231-MIBG, one received 370 MBq 1311-MIBG) and four
received a therapeutic dose of MIBG [3.7 GBg '311-MIBG]). Scans were evaluated by
blinded investigators, and sites were confirmed by histologic examination of surgical
specimens for chromaffin tissue when available. SRS identified at least one lesion in nine
of 10 subjects with pheochromocytoma while MIBG identified tumor in eight of 10.
MIBG, however, localized over 80 lesions in these patients, while octreotide only identi-
fied 28. Soft tissue lesions were identified equally well with both techniques, although in
general, the intensity of uptake was greater for MIBG. MIBG was superior, though, for
the localization of bone metastases [26]. Overall, octreotide identified only 43 percent of
sites seen by the diagnostic MIBG scans, and only 24 percent of the sites identified on
therapeutic MIBG. Octreotide scanning fared far better in the three subjects with para-
gangliomas identifying at least one site in all three patients and eight sites overall, com-
pared to the nine sites seen by MIBG in the three subjects.
There was one pathologically confirmed lung metastasis that was missed by MIBG
but identified by octreotide. However, the abdominal primary in this same patient was
missed by octreotide but seen on MIBG. This raises the possibility that octreotide scan-
ning may be complementary to MIBG scintigraphy. This concept was tested further by
Krenning and colleagues in an analysis ofeightpatients with pheochromocytoma and four
subjects with paraganglioma. Two patients with pheochromocytoma who received both
scans had more lesions seen with octreotide, while two had more lesions seen with MIBG.
Four patients had the same number of lesions visualized. Three out of four patients with
paragangliomas had more sites identified with octreotide than MIBG [23]. Therefore, the
sensitivity of these nuclear imaging techniques appears to depend on type of tumor and
suspected location of metastases. MIBG appears more sensitive for pheochromocytoma
metastases to bone, while octreotide may be preferred for pheochromocytoma metastases
to lung and for cervical paragangliomas [23, 26]. Future studies comparing SRS to MIBG
utilizing a consistent amount of nucleotide in each subject are needed to more accurately
assess the relative sensitivities ofthese techniques as dosimetry affects the diagnostic sen-
sitivity of radionucleotide imaging.
Clinical algorithmsfor SRS in Cushing's syndrome andpheochromocytoma
A critical question for the clinician is the appropriate use ofradionuclide imaging in
the management of a patient with either a suspected or pathologically confirmed case of
Cushing's or pheochromocytoma. Until further prospective studies are completed, which
would establish the sensitivity, specificity and cost effectiveness ofSRS, clinicaljudgment
will dictate its use on a case-by-case basis [27].
The diagnosis of ACTH-dependent Cushing's syndrome should be established bio-
chemically prior to any imaging being performed (Figure 1). Next, a dexamethasone sup-
pression test and a pituitary MRI is performed to localize the lesion. A diagnostic sup-
pression test in conjunction with a localization by pituitary MRI is followed directly by
surgical resection ofthe identified lesion. Negative pituitary MRI in conjunction with non-
diagnostic suppression or markedly elevated ACTH levels strongly suggests a peripheral
source and should be initially followed by SRS and chest and abdominal CT scans to
localize the tumor. A positive localization will avoid the invasive IPS procedure in these
patients. Other cases in which the dexamethasone suppression test and pituitary MRI pro-
vide conflicting data require IPS sampling for ACTH to confirm if the lesion is central or
peripheral. Ifthe IPS sampling suggests a peripheral source, SRS and CT scanning should
now be performed to localize the tumor. When the source cannot be localized by any tech-
nique, medical management or bilateral adrenalectomy is considered. All localized tumors
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Figure 1. Octreotide scan in the differential diagnosis of ACTH-dependent Cushing's syn-
drome. a) 2 mg dexamethasone by mouth every six hours for48 hours; b) MRI: magnetic resonance
imaging; c) Suppressed: >90 percent suppression ofurine free cortisol or >64 percent suppression
of 17-hydroxycorticosteroids from baseline urine [16]; d) IPS: inferior petrosal sinus sampling for
ACTH; e) SRS: somatostatin receptor scintigraphy with lllln-pentetreotide; f) CT: Computed
tomography. g) Positive Sampling: peak IPS: peripheral ratio ofACTH greater than 3.0 with CRH
administration [16].
are resected. Pheochromocytomas and paragangliomas should first be diagnosed bio-
chemically and then localized with MRI (Figure 2). If a benign appearing adrenal mass is
identified, the patient may proceed directly to surgical resection. If no mass is seen, an
octreotide scan orMIBG scan is performed to localize the source. Choice ofscan depends
upon availability and local expertise. A positive scan avoids the need for invasive venous
sampling. In adults, 10 percent ofpheochromocytomas may be ectopic, 10 percent malig-
nant and 10 percent bilateral [10]. Extra-adrenal and malignant lesions identified by MRI
should be confirmed with nuclear imaging to document the neuroendocrine nature of the
lesions and to rule out extra-abdominal metastases. Patients with persistent post-resection
hypertension and catecholamine excess would also benefit from a follow-up nuclear scan
to rule out recurrent or residual disease that may be obscured by post-operative changes
on MRI.
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Figure 2. The role of somatostatin receptor imaging in the staging of pheochromocytoma. a)
MRI: magnetic resonance imaging; b) SRS: somatostatin receptor scintigraphy; c) MIBG: meta-
iodobenzylguanidine; d) Venous sampling: venous catheterization with sampling for cate-
cholamines along the superior and inferior vena cava [20].
CURRENT SENSITIVITY AND SPECIFICITY OF SRS
Several caveats must be kept in mind when using somatostatin receptor scintigraphy
for the identification of adrenal tumors. There has been no study published to date that
adequately addresses the specificity of SRS. It is known, however, that activated lympho-
cytes overexpress somatostatin receptors. Positive octreotide scans, therefore, occur in
sites ofgranulomatous disease (23 of23 cases ofsarcoid, four offour cases ofWegener's,
and six of six cases of tuberculosis) and in cases of autoimmune inflammation (nine of
nine cases ofuntreated Graves' hyperthyroidism) [23]. Localized sites ofabscess orinfec-
tion or active sites ofrheumatoid arthritis will also result in a positive scan. Up to 75 per-
cent ofbenign, non-functioning pituitary adenomas may overexpress somatostatin recep-
tors (12 of 16) [23].
The current clinical case series published to date suggest a diagnostic sensitivity of
up to 86 percent for benign pheochromocytomas but as low as 24 percent for pheochro-
mocytoma metastases [23, 26]. False-negative scans occur in tumors that do not express
receptors. Only 38 of 52 pheochromocytomas (73 percent) examined in one study were
SSTR positive in vitro [11]. False-negative scans may also occur if tumor somatostatin
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receptors are down-regulated by endogenous somatostatin production. In one study, 23 of
41 pheochromocytomas tested SRIH positive (56 percent) with three ofthree ofthese pos-
itive for SRIH mRNA, confirming local production ofthe hormone [11]. Prior exogenous
administration of a somatostatin analogue may also down-regulate receptor expression by
tumor. False-negative scans may occurbecause indium-labeled octreotide is clearedby the
kidneys, making imaging of the nearby adrenal glands difficult [23]. Finally, tumors that
express a different subtype of somatostatin receptor that the octreotide does not recognize
will also be missed by this imaging technique [13, 23]. Octreotide recognizes SSTR2,
SSTR3 and SSTR5. Pheochromocytomas rarely overexpress SSTR3 or SSTR5 [5].
Therefore, imaging is dependent chiefly upon the pheochromocytoma overexpressing
SSTR2. In a series ofeight pheochromocytomas, SSTR2 and SSTR4 were the most abun-
dantly expressed, but SSTR2 only accounted for 40 percent of the overall SSTR expres-
sion by these tumors [5]. The development of new somatostatin analogues with different
receptor subtype specificities will be critical to enhancing the sensitivity of SRS for the
imaging ofpheochromocytomas.
TARGETING SOMATOSTATIN RECEPTORS FOR TREATMENT
Targeting somatostatin receptors in patients with tumors producing Cushing's syn-
drome has met with limited success. Single dose treatment of nine patients with ACTH
dependent Cushing's syndrome with either somatostatin (five patients, 500 micrograms
intravenous infusion over 60 minutes) or octreotide (four patients, 100 micrograms sub-
cutaneous injection) did not lead to a clinically or statistically significant change in plas-
ma ACTH levels in any patient. In the same study, five other patients with pituitary
Cushing's disease did not have a change inACTH or cortisol response to 1 microgram per
kilogram body weight CRH intravenous after a single treatment with octreotide [28]. In a
separate case report, two patients treated with octreotide (100-150 micrograms subcuta-
neously every eight hours for five to seven days) had no clinically significant decrease in
24-hour urine free cortisol, serum cortisol orACTH levels [29]. Thus, short-term therapy
of unselected cases of Cushing's with somatostatin analogues is ineffective. Targeting
those tumors that overexpress somatostatin receptors based on a positive localization with
SRS may prove more effective in specific cases.
Sustained therapy for one month with sandostatin, a long-acting somatostatin ana-
logue (400-1200 micrograms daily intravenous or divided subcutaneously every eight
hours for 24-49 days), has proven effective in its ability to decrease the serumACTH lev-
els ofthree out of three patients with pituitary Cushing's disease requiring medical thera-
py [30]. Another patient with paraneoplastic cortisol hypersecretion reported in the same
paper was noted to have asignificantdecrease in serumACTH levels as well as a sustained
decline in urine free cortisol excretion. The literature also contains a single report of a
patient who received symptomatic relieffrom sustained therapy with a somatostatin ana-
logue for a hormonally active, metastatic, adrenal cortical carcinoma that was resistant to
standard chemotherapy [31]. Thus, sustained medical therapy with parenteral somato-
statin analogues may be considered as an option to provide symptomatic reliefto patients
with adrenal cortical stimulating tumors who are non-operative candidates. Risks and
benefits ofthis therapy should be balanced with the risks and benefits ofmore established
medical therapies [14].
Clinical experience with octreotide as a therapeutic agent forpheochromocytoma has
not met with success to date. Ten patients with pheochromocytoma in a crossover, place-
bo-controlled trial were given either three doses of 100 micrograms ofoctreotide orplace-
bo subcutaneously over 24 hours. Blood pressure and serum and urine catecholamines
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were monitored pre- and post-dosing. No change in blood pressure or plasma and urine
catecholamines were noted overall. Two of the patients with the highest density of
somatostatin receptors on their tumors were noted to have a modest decrease in norepi-
nephrine levels, but this did not translate into a lower blood pressure [32]. Other investi-
gators have shown a fall in norepinephrine and epinephrine levels in six patients treated
with 50 micrograms ofintravenous octreotide infused over two hours, but without a con-
sistent effect on blood pressure [33].
FUTURE DIRECTIONS
A promising area for the therapeutic use ofoctreotide in adrenal tumor management
is to deliver a toxic dose of a radioactive substance directly to tumor cells. Similar tech-
nology has been used with 13'I-MIBG, but most tumors respond incompletely andbecome
rapidly resistant to this particular therapy [26, 10]. Radiolabeled somatostatin analogues
designed for therapeutic purposes are currently undergoing clinical trials [13].
CONCLUSION
In summary, somatostatin receptors are present on both normal adrenal cortex and on
tumors producing an excess ofadrenal cortical hormones. Imaging ofprimary adrenal cor-
tical lesions is limited by renal clearance of octreotide and a low somatostatin receptor
density. Ectopic or metastatic lesions may be visualized and may partially respond to sus-
tained exogenous treatment with somatostatin analogues. Non-adrenal carcinoid tumors
secreting hormones, which stimulate the adrenal gland to overproduce cortisol, are able to
be visualized by octreotide. Early useofoctreotide scanning may help avoidinvasivediag-
nostic and surgical procedures in patients whose tumors express somatostatin receptors.
The majority of pheochromocytomas and paragangliomas express a high density of
somatostatin receptors, and many may be visualized with currently available radiolabeled
somatostatin analogues. Further investigation is needed to establish its sensitivity and
specificity compared with existing technologies, but clinical use may be considered in
patients with documented catecholamine excess and negative or equivocal localization
studies.
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